drugset / Trial / NCT04506138
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma
Timeline
- Start
- 2020-08-11
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | — |